SCHEMBL1715907

SCHEMBL1715907

COc1cccc(-c2ccccc2CON)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 7/20 0.54
AGXT P21549 2/20 0.54
HTR7 P34969 1/20 0.49
ABCB1 P08183 1/20 0.46
ABCC1 P33527 1/20 0.46
TDO2 P48775 1/20 0.46
MGAT2 Q10469 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
MAOB P27338 2/20 0.44
PTGER1 P34995 1/20 0.44
PTGER4 P35408 1/20 0.44
PTGER3 P43115 1/20 0.44
PTGER2 P43116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
BRD4 O60885 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8279410 0.84 MGAT2 (0.57) HTR7ABCB1ABCC1TDO2MGAT2
Hydrochloric Acid SCHEMBL12490805 0.83 MGAT2 (0.56) HTR7ABCB1ABCC1TDO2MGAT2
SCHEMBL28854331 0.81 HTR7 (0.51) HTR7ABCB1ABCC1TDO2MGAT2
SCHEMBL2020140 0.79 ABL1 (0.59) ABCB1TDO2ADORA2AADORA1MAOB
SCHEMBL6048529 0.78 BACE1 (0.58) HTR7ABCB1ABCC1MAPT
SCHEMBL952649 0.78 HTR7 (0.49) HTR7ABCB1ABCC1TDO2MGAT2
SCHEMBL17295958 0.78 ABCB1 (0.52) HTR7ABCB1ABCC1MAOBPTGER1
SCHEMBL8281062 0.78 HTR7 (0.52) HTR7ABCB1ABCC1CD274BRD4
SCHEMBL9890742 0.78 MTNR1A (0.50) HTR7ALDH1A1LMNAMAPTHSD17B10
SCHEMBL1521309 0.77 DPP4 (0.59) IDO1AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 IDO1 3029/4885AGXT 131/4885HTR7 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.